GKCAS 2020 Annual Allergy and Asthma Meeting

Overland Park, KS US
January 25, 2020

This annual meeting will provide up-to-date, evidence based, practice information on oral immunotherapy, biological medications and primary immunodeficiency disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours.

Commercial Support
This activity is supported by educational grants from CSL Behring, DBV Technologies, Genentech, and Kaleo


Target Audience

Primary care physicians
Allied healthcare providers

Learning Objectives

At the conclusion of this meeting, learners should be able to:
1. Discuss various diagnostic tests available for primary immunodeficiency disorders
2. Employ the latest recommendations in regard to performing oral immunotherapy in their practice
3. Differentiate between various allergic skin conditions and learn management strategies for these conditions
4. Assemble various biological medications and their risks and benefits
5. Integrate the material discussed at the meeting into their current practices


Additional information

Disclosure Policy 
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 


Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
Course expires: 
Event starts: 
01/25/2020 - 7:15am CST
Event ends: 
01/25/2020 - 1:00pm CST
Johnson County Convention Center
8788 Metcalf Avenue
Overland Park, KS 66212
United States

All identified conflicts of interest have been resolved.

RIchard Wasserman, MD
Consultant: DBV Technologies

Ronald Balkissoon, MD
Speaker, consultant, advisory board: Astrazeneca, Genentech, Sanofi, Regeneron, Glaxo Smith Kline, Novartis
Consultant: Bayer

Jennifer Leiding, MD
Speaker, consultant: CSL-Behring
Speaker, consultant, receive Grant research funding: Horizon Pharma
Consultant:  Orchard Therapeutics

Marc Serota:
Consultant for Regeneron, Sanofi-Genzyme, Genentech, Novartis, Pfizer, Celgene

The following have no financial relationships to disclose:
Sadia Hayat, MD
Nikita Raje, MD
Neha Patel, MD
Salman Aljubran, MD
Brenda Snyder, APRN

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.